Status:
COMPLETED
Evaluate the Pharmacokinetics of BMS-986177 From Two Formulations in Healthy Participants
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Thrombosis
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
Assess the pharmacokinetics (fasting and fed), safety, and tolerability of BMS-986177 following oral dosing of Form A and Form B
Eligibility Criteria
Inclusion
- Body mass index 18.0 to 32.0 kg/m2, inclusive
- Women must not be of childbearing potential (cannot become pregnant)
Exclusion
- Any significant acute or chronic medical illness
- Head injury in the last 2 years
- History of bleeding disorder including rectal bleeding (ie, hemorrhoids), spontaneous nosebleeds, etc.
- Other protocol defined inclusion / exclusion criteria could apply
Key Trial Info
Start Date :
November 15 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 28 2017
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT03362437
Start Date
November 15 2017
End Date
December 28 2017
Last Update
March 14 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Quotient Clinical
Ruddington, Nottingham, United Kingdom, NG11 6JS